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ABSTRACT 
 
 
 
JAMES ROKOS: Immunohistochemical Evaluation of Sex Steroid Hormones in 
Sicca Syndrome Patients 
(Under the direction of Ricardo J. Padilla,DDS; Michael T. Brennan,DDS; & Dr. 
Valerie A. Murrah, DDS,MS;) 
 
Sjögren syndrome (SS) is a chronic autoimmune disease affecting mainly climacteric 
females. The coincidence of sex hormones decline and higher prevalence of SS in 
this population implies that such hormones participate in its pathogenesis.  Their 
exact role in the pathogenesis of SS is still controversial.  This study investigates the 
presence and location of sex hormone receptors within minor labial salivary glands 
(MLSG) in a cohort of sicca syndrome patients being evaluated for SS.  An 
immunohistochemical comparison of the ratio of estrogen receptors (ER) to 
androgen receptors (AR) expression was correlated to the patients’ focus score 
(FS).  A greater intensity of androgen receptor expression in SS patients, especially 
in the nucleus of acinar cells was found when compared to the other receptors 
(p<0.001). However, no statistically significant difference was found in the ratio of 
ER to AR as a function of FS in our group of patients. 
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INTRODUCTION 
 
Sjögren Syndrome (SS) is an autoimmune disease with debilitating oral sequelae. It 
is the second most common rheumatic disease in the US, affecting between 2 and 4 
million people, and it typically afflicts climacteric females nine times more often than 
men. (1); 292 Fox,R.I. 2005}}It has been hypothesized that the coincidence of the 
hormonal decline and the rise in prevalence in Sjögren Syndrome implies that sex 
hormones play a role in the pathogenesis of the disease. (2,3)(4)Research has 
shown that both estrogens and androgens are involved in the development, 
differentiation, and normal functioning of the salivary glands. In addition, withdrawal 
of these sex hormones, in both human and animal models leads to glandular 
dysfunction. (5,6) In other autoimmune processes, androgenic influence curtails the 
severity of the inflammatory response, and estrogenic participation enhances it. 
(7)Yet, in SS, the typical age of onset is during a time when both androgens and 
estrogens are declining. 
 
Despite extensive research to explain the role of sex hormones in the pathogenesis 
of SS, most of the answers still elude explanation.  Conflicting theories abound as to 
whether the disease is caused by an androgenic deficiency, an estrogenic 
deficiency, or a combination of the two.(8-14) Contributing to this lack of knowledge 
 2 
 
is the fact that very little is known about the normal expression and distribution of 
receptors for the active hormones in the affected glands. 
 
It is the intention of this study, to contribute to the knowledge and understanding 
concerning the role of sex hormones in SS. Through immunohistochemical staining 
of sex hormone receptors, we will investigate if there is a difference between the 
expression of androgen (AR), estrogen receptors (both ER-α and ER-β), and 
progesterone receptors (PR) in the minor labial salivary gland (MLSG) tissue of a 
cohort of patients who have some, but not all the diagnostic criteria of primary SS.  
In addition, a sample of age-matched female patients, who have had lower labial 
biopsies for other reasons that incidentally include MLSG tissue will be used for 
observation and comparison of the normal receptor expression.  The ratio of ER to 
AR will be compared between the groups in its relationship to focus scores (FS) (i.e. 
FS ≥1 vs. FS<1 vs. control). We hypothesize that the ratio of ER to AR will increase 
as FS increases. 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
 
Sjögren’s Syndrome is a common autoimmune disease with serious oral 
sequelae and an increased risk of malignancy 
 
Sjögren’s Syndrome (SS) is an autoimmune exocrinopathy first described by 
Mikulicz in 1892 and then further characterized by the Swedish ophthalmologist, 
Henrik Sjögren, in 1933. (15) At the time of its recognition by Mikulicz, the patient 
presented with bilateral enlargement of the parotid glands which, upon histologic 
examination, were focally infiltrated with lymphocytes. Sjögren went on to describe a 
cohort of women who had clinical symptoms of dry eyes, dry mouth, and probable 
rheumatoid arthritis in addition to similar histologic findings as Mikulicz’s patient. 
Keratoconjunctivitis sicca was the term Sjögren introduced for this constellation of 
signs and symptoms. It was later proven by Morgan and Castleman that both 
Mikulicz’s and Sjögren’s patients had identical histologic features. In 1956, Bloch et 
al outlined the features common to what we now know as Sjögren’s syndrome 
(SS).(16,17) 
 
Sjögren syndrome is the second most common autoimmune rheumatic disease in 
the US, affecting 2-4 million people. (1,18) Primary SS is characterized by a 
lymphocytic infiltrate of the exocrine glands, most significantly the lacrimal, 
meibomian, and salivary leading to a characteristic keratoconjunctivitis and 
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xerostomia. When seen unaccompanied by other connective tissue diseases, such 
as rheumatoid arthritis, systemic lupus erythematosis, or scleroderma it is 
considered primary SS. When seen in combination with these other diseases it is 
considered secondary SS. The incidence of primary SS equals that of secondary 
SS. (18) 
 
The defining qualities of the exocrine involvement of the disease have many quality 
of life ramifications. The keratoconjunctivitis sicca caused by profound aqueous tear 
deficiency and decreased lipid content, can lead to corneal abrasions and secondary 
bacterial and fungal infections. Of greatest concern is the development of sterile or 
microbial corneal ulcerations and subsequent blindness. (16)(19) Direct effects of 
xerostomia include: atrophy of the mucosa and associated discomfort; difficulties in 
swallowing, chewing, and speaking; diminished taste; and decrease nutrition. In 
addition, further complications due to xerostomia can include increased risk of dental 
caries, and increased frequency of bacterial and fungal infections. These, in turn, 
can cause secondary stomatodynia (18)  
 
Despite the quality of life issues associated with the glandular sequelae of SS, extra-
glandular involvement is also significant. Generalized xerosis, affecting other 
mucosal surfaces besides the ocular and oral, are frequently reported: dryness of 
the nose; throat; skin; and vagina are common. Systemic manifestations of SS can 
involve peripheral neuropathies, myalgias, arthralgias, thyroid disorders like 
autoimmune thyroiditis, and pulmonary and renal pathosis. (18) (20) 
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One of the most serious complications of SS is the increased relative risk for 
malignant lymphoma seen in this patient population. Originally it was reported that 
primary SS patients had an increased relative risk of developing a lymphoma as high 
as 44.4 times normal, mainly of the MALT type (low grade).(21) This was based on 7 
cases of lymphoma in 142 patients over a 29 year period of time. In a meta-analysis 
of autoimmune associated lymphoma risk, Zintzaras showed that non-Hodgkin 
lymphoma (NHL) is more common in patients with autoimmune diseases, and SLE 
and primary SS showed the greatest association. However the standardized 
incidence ratios (SIR) from the various studies occurred over quite a broad range 
(8.7-44.4).(22)  More recently the upper limit of this range has come under scrutiny. 
Theander, et al re-evaluated the relative risk to be more realistically 16 times higher 
than the general population. Moreover, the type of lymphoma that is more likely to 
develop is a diffuse large B-cell type (DLBC) and a CD4+ T cell lymphocytopenia 
was found to be a strong risk factor for lymphoma development. (23) 
 
Diagnosis of SS is based on a combination of signs and symptoms not unlike other 
rheumatic diseases.  Since no single diagnostic test to indicate or exclude the 
diagnosis of SS exists, the current diagnostic criteria include a combination of 6 
subjective and objective findings the patient must possess. These include: subjective 
ocular symptoms; subjective oral symptoms; objective ocular signs such as a 
positive Shirmer’s test or Rose Bengal score;  histopathological evidence of disease 
such as a minor labial salivary gland  (MLSG) biopsy with a focus score  ≥ 1;  
objective evidence of salivary gland involvement by an assessment of unstimulated 
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salivary flow, salivary scintigraphy, or parotid sialography; and laboratory 
abnormalities as evidenced by the presence of autoantibodies, SS-A (Ro) ,SS-B 
(La), or rheumatoid factor. (24) None of these criteria by themselves is specific to SS 
and several are common to several autoimmune diseases. This has led to numerous 
criticisms of the American-European classification system, and other diagnostic 
classification schemes being proposed. (25,26)(27) This lack of agreement makes 
the diagnosis of SS somewhat problematic and inconsistent. By extension, this 
complicates collaboration between care providers utilizing different diagnostic 
classifications, and thwarts efforts to develop treatment strategies, and study their 
effectiveness. 
 
SS affects women more frequently than men 
 
Although men and children can present with SS, the disease primarily affects 
middle-aged women nine times more often than men. (28)(29)(30) It is this female 
dominance and late age of onset that leads investigators to question the role of sex 
hormones in the pathoetiology of the disease. 
Sjögren syndrome affects women 9 times more often than men.(31)(18) It is not 
alone in this gender differential. Other autoimmune disorders that preferentially 
affect women include rheumatoid arthritis (2-4:1), systemic lupus erythematosis (5-
13:1), scleroderma (3:1), and Graves' disease (4-8:1).(32-34)(31) As gender 
appears to be a risk factor in all of these diseases, sex steroid hormones, especially 
estrogens, may be mediators of the process. Sex hormones influence both humoral 
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and cell mediated immune responses.(7)(35) Furthermore, estrogens have been 
shown to have a perpetuating effect on inflammatory conditions. (36,37)(38) (14) By 
contrast, testosterone has been shown to ameliorate autoimmune inflammation in 
systemic lupus erythematosis (SLE) models and in the target organs affected by 
SS.(39)(40)(41)(42)(43)  
 
SS mainly affects perimenopausal women, why then? 
 
Epidemiological data indicates that fertile age women are more affected by 
rheumatic autoimmune diseases than men, probably owing to a higher concentration 
of pro-inflammatory estrogens.(44) This would seem likely given the dramatic 
decrease in incidence in other autoimmune diseases like SLE after menopause.(45) 
So then why would an autoimmune disease, such as SS, have its genesis in the 
perimenopausal female?  
 
During menopause, serum concentrations of sex-steroid hormone are declining in 
women, due to a regression of the gonadal production of testosterone and 
estrogen.(46) However, there are two sources for androgens and estrogens in the 
body. One is the well known gonadal source, but additionally there are sex steroid 
precursors, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate 
(DHEA-S), produced by the adrenal cortex and converted peripherally in target 
tissues to either androgens or estrogens depending on the tissue need or local 
conditions. This peripheral production is not organ specific, nor even tissue specific, 
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but can be different for each individual cell. When introduced, this new sector of 
endocrinology, called intracrinology highlighted the subtle, cellular control peripheral 
tissues have over the formation of sex hormones.(47). In adult human males, 50 % 
of all androgens are derived from adrenal precursors. In women, 75% of estrogens 
are produced peripherally prior to menopause, and 100% after menopause. (47) 
Moreover, women produce 66% as much androgens as men from DHEA.(48)  
Therefore, serum measurement of either androgens, estrogens, or their adrenal 
precursors may not reflect a true profile of the patient’s hormonal status. 
 
A similar phenomenon to menopause, called adrenopause, occurs synchronously. It 
is characterized by a functional decline in the secretion of DHEA and DHEA-S from 
the adrenal cortex.(49)(48).   
 
Is it this decline in both gonadal and adrenal hormones the cause for SS being seen 
most likely in climacteric females? Sullivan demonstrated that postmenopausal 
females are not just estrogen deficient; they are also androgen deficient as well.(2). 
His study showed a serum deficiency in DHEA, 5-androstene-3β, 17β-diol (5-diol), 
DHT, androsterone glucuronide (ADT-G), and androstane-3α,17β-diol-G (3α-diol-G) 
in SS patients compared with age-matched controls, but it did not find decreased 
serum concentrations of androstenedione, testosterone, estrone, or 17β-estradiol. 
Like Sullivan, Valtysdottir, et al showed that SS patients had lower serum 
concentrations of the adrenally produced pro-hormones compared with controls. (50) 
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Taiym, et al showed significantly higher serum levels of prolactin, and higher ratios 
of prolactin/progesterone and estrogen/progesterone between SS patients and 
healthy age-, sex-, race-matched controls. No significant differences were detected 
in the levels of estrogen or progesterone alone.(51) 
 
 Sullivan’s group reported that androgen deficiencies may play a critical role in 
autoimmune dry eye syndromes such as SS.(8) Furthermore, it was shown that 
estrogen and progesterone promoted the development of dry eye symptoms in 
women, especially those who were taking hormone replacement therapy or who 
were pregnant.(9,10,13)   In addition, Nagler, et al presented 2 cases of previously 
healthy young women who developed SS following in vitro fertilization therapy.(12) 
Conversely, Ishimaru, et. al., using animal models, suggested that it is an estrogen 
deficiency that leads to the exocrinopathy typical of SS.(11,52) Hayashi, et al 
proposed that an estrogen deficiency promoted the production of auto antigens 
within the gland parenchyma.(53) 
Yet serum may not be an accurate assessment of the sex hormone status of SS 
patients. More recently, Porola, et al has demonstrated not only low serum 
concentrations of DHEA and DHT in SS patients, but went to show that salivary 
concentrations of the pro-hormone and its end –product (DHT) were also low.(54) 
This reflects a more accurate picture of the intracrine processing and the sex 
hormone levels within one of the main target organs of SS. 
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Why are the exocrine glands preferential targets of SS? 
 
The main exocrine glands involved in SS are the lacrimal (LG), the meibomian (MG), 
and the salivary glands (SG). In various mammalian species, including humans, 
there is evidence highlighting the gender differences in these structures. These 
differences include morphologic, physiologic, and even immunologic differences. For 
example, in the lacrimal gland of both mice and rats, the size and shape of the 
lacrimal acini are larger and more irregular in the males and smaller and more 
regular in the females. In hamsters, males have higher number and affinities of β-
adrenergic binding sites compared to females, and females have greater amounts of 
melatonin and N-acetyltransferase compared to the males. Immunologically, male 
rats show a higher synthesis of secretory component, greater production of IgA, and 
an increased number of IgA-containing cells compared to females. Most significant 
of all is the greater incidence of autoimmune diseases in the lacrimal glands of 
mouse and human females.(55) Moreover, these types of sex-related differences 
extend to the salivary glands of various species as well. (56,57) 
 
Sex-related differences can be appreciated at the genomic level as well. Señorale-
Pose, et al showed that the Vcs2 gene is differentially expressed in the acini 
epithelium of the submandibular gland of mice according to gender. No Vcs2 
transcripts were detected in the female submandibular gland. Moreover, transcripts 
were lost upon orchiectomy of male mice and induced in females by androgen 
administration.(58) 
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In 2006, Richards et al showed significant differences in gene expression in over 
490 different genes when comparing male and female mouse lacrimal glands using 
microarray and rt-PCR assays.(59) In addition, Treister et al demonstrated tissue-
specific sex-related differences in gene expression if the BALB/c mouse major 
salivary glands.(5) 
 
Androgen target: a theory for sex-related differences 
 
Considering that sex related differences in species is under the influence of sex-
steroid hormones, research was undertaken to determine whether androgens or 
estrogens predominated in the development, maintenance, and normal functioning 
of these glands. Through manipulation of androgenic influences, studies have shown 
that the LG, MG, and SG are androgen target organs. If mice, rats, hamsters, guinea 
pigs and/or rabbits are castrated or are treated with an androgen receptor antagonist 
degenerative changes ensue in the LG. (55). Decreased growth and functional 
activity, disappearance of glandular elements, and attenuation of acinar cell size are 
but a few of the changes observed. Moreover, if androgens are exogenously 
replaced following orchiectomy, LG structure and function can be restored and, in 
some cases, even lead to acinar cell hyperactivity.  
 
In the submandibular glands of male and female mice, there was an observed 10 
fold increase in the activity of glucose-6-phosphate amino transferase (G6P-AT) in 
the females. If the mice were ovariectomized, no change in activity was observed. If, 
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however, testosterone was injected into the female mice, the activity of the G6P-AT 
was reduced to the normal male level. Conversely, if male mice were given 17β- 
estradiol no change in their G6P-At activity was noted, but, upon castration, the level 
rose to that of the normal female glands.(60) This would suggest that the influence 
of estrogens is secondary to that of androgens in the glands. It was also shown that 
ovariectomized female mice subsequently treated with testosterone differentially 
expressed 500 genes compared to controls. Interestingly, 214 of these genes were 
also expressed by androgen treated male mice, but many were unique to the 
females.(6) 
 
On a molecular level, Richards, et al showed that 2000 genes were regulated by 
testosterone in the mouse LG. He used orchiectomized or testicularly feminized 
mice that were given testosterone implants.(61) Similar results were observed by 
Treister, et al when looking at the magnitude of the effect androgens have on 
submandibular gland of the BALB/c mouse. Orchiectomized male mice were 
implanted with a subcutaneous pellet containing either slow-release testosterone in 
a vehicle or just the vehicle. It was shown that androgens significantly influenced the 
expression of over 1300 genes, 366 of them had been previously shown to be 
differentially expressed by males.(5,62) 
 
Similar evidence of androgenic influence on the meibomian gland has also been 
discovered. Given the fact that the MG is a large sebaceous gland, and elsewhere in 
the skin, sebaceous glands fall under androgen control, it is not remarkable that this 
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ocular gland would also be an androgen target. Sullivan, et al, using 
immunohistochemistry (IHC) found androgen receptor (AR) protein in the nuclei of 
both male and female rat meibomian acinar epithelium. Also, when examining rabbit 
MG following castration, the application of topical ocular 19-nortestosterone or 
systemic 19-nortestosterone lead to significant differences in the lipid content profile 
of the glandular acini without affecting gross morphology.(63) 
 
In 2005, Schirra, et al went on to show that in castrated, male, mouse MG, 
testosterone administration significantly influenced the expression of 1590 genes 
compared to control treated mice.(64)  
 
The presence of AR in human ocular tissues was demonstrated by Rocha, et al. The 
AR was located in the epithelial cell nuclei in the LG and in acinar epithelial nuclei in 
the MG. In addition 5α-reductase mRNA was also identified. This enzyme catalyzes 
the conversion of dehydroepiandrosterone (DHEA) to the potent active metabolite, 
dihydrotestosterone (DHT).(65) (66) Moreover, Wickham, et al demonstrated 
estrogen receptor (ER), progesterone receptor (PR) and AR mRNAs in various 
ocular tissues in various mammalian species including humans using rt-PCR. Their 
results confirmed the presence of AR, ER, and/or PR in tissue from the LG and MG 
of rats, rabbits, and humans.(67) 
 
 Li, et al demonstrated AR localization, using IHC, in the serous acini and ductal 
epithelium of the submaxillary glands of  male rats independent of whether the 
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animal had been castrated or not.  AR mRNA was localized utilizing in situ 
hybridization to the epithelial cells of the convoluted, the secretory, and the excretory 
ducts in the control groups only. In the castrated males the AR mRNA was confined 
to the convoluted and secretory ducts only. An overall reduction in the quantity of AR 
in the gland was observed following castration. (68) Laine, et al showed AR in the 
serous, mucous, and ductal epithelial nuclei of normal human salivary gland.(69) 
 
Is SS mediated by an androgen deficiency, an estrogen deficiency, or an 
interaction of the two? 
 
Numerous studies have addressed why the glandular effects of SS may be mediated 
by sex hormones. It has been demonstrated in the MRL/lpr mouse model of SS that 
the lacrimal lymphocytic lesions can be suppressed with androgen 
treatment.(70)Sullivan demonstrated that anti-inflammatory benefits of androgen 
treatment in this animal model, and also an enhanced functional output as measured 
by total amount of IgA secretion in the saliva.(43) Conversely, if androgens are 
deficient one would expect an increase in lacrimal inflammatory lesions, and a 
decrease in glandular function. This was tested using testicular feminized mice, 
castrated rats, rabbits, guinea pigs, and human males receiving androgen 
antagonists. No correlation between androgen receptor dysfunction and increased 
lacrimal gland or submandibular salivary gland inflammation was observed in all the 
animal models. Moreover, no decrease in tear volume was noted in the mice o(71)r 
in the human males.(71)  
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In a similar assessment of the androgenic influence in the meibomian glands of the 
eye, Sullivan, et al found striking evidence of meibomian dysfunction and SS-like 
evaporative dry symptoms in humans receiving androgen antagonists. These 
symptoms included: greater frequency of tear film debris; abnormal tear menisci; 
metaplasia of meibomian gland orifices; reduction in the quality of secretions; and an 
increase in blurred vision, light sensitivity, and painful eyes.(72) 
 
Estrogen receptors (ER) were identified in the rat submandibular and parotid glands 
in ovariectomized females.(73) There was found to be a differential expression of ER 
between the two glands with the submandibular gland containing a significantly 
higher concentration of ER. Camacho-Arroyo showed that ER and PR were located 
mainly in the acinar nuclei of female and male rabbits. Timing during estrous, 
whether the animal had been castrated, or castrated and estrogen treated 
determined the concentration of both ER and PR with a decreasing trend, 
respectively. Male rabbits showed lower concentrations of the receptors than 
females.(74) 
 
Estrogens also have been shown to have a target tissue in the oral cavity, most 
notably, the epithelia of the surface mucosa and salivary glands.(75)(76) This 
becomes evident when levels of estrogen fall and the mucosa atrophies and salivary 
function decreases as is seen during menopause. (77,78)  Furthermore, these 
symptoms can be ameliorated by the re-establishment of normal estrogen blood 
levels with hormone replacement therapy (HRT).  
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Interestingly, in 2000, Esmaeli, et al showed that the conjunctiva and accessory 
lacrimal glands were devoid of either AR, ER, or PR. In the MG sampled, he gave 
evidence for ER in the human MG (22 of 22), but, was able to demonstrate AR and 
PR in only 1 of 22 specimens.(79) This is in distinct contrast to other sebaceous 
glands of the skin and scalp. 
 
 ER-α and ER-β mRNA was also found in human LG.(80) By contrast, ER-α was not 
detected in oral buccal or gingival epithelium or in SG. The other isoform, ER-β was 
widely expressed in all oral tissues especially keratinocytes and acinar and ductal 
SG epithelium. (75) 
Obviously, a controversy exists between the interplay of androgens and estrogens in 
the pathogenesis of SS. There is most likely a delicate balance between androgenic 
and estrogenic influences leading to the exocrinopathy indicative of SS that remains 
to be uncovered.  Furthermore this delicate balance appears not at the system or 
organ level, but peripherally, at the tissue and cellular level. Peripheral production of 
these hormones may hold the key to this controversy. Porola, et al have shown that 
within the milieu of a systemic androgen/DHEA deficiency, there is also a suspected 
defect in the intracrine enzymatic machinery causing a lack of androgens to be 
produced at the cellular level and an over production of estrogens.(54) Furthermore, 
the enzymes which catalyze the conversion of DHEA to DHT or estradiol, 5α-
reductase and aromatase, respectively, were found to be distributed differently 
within the cytosol of SS patients when compared to healthy controls.(81)   
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Local factors, such as the presence of cytokines and circulating cortisol may push 
the equilibrium towards an androgenic environment or to one that is more 
estrogenic. (82) Cutolo showed that the cytokines IL-1, IL-6, and TNF-α stimulated 
aromatase activity in RA patients synovium.(44) Rocha had previously shown that of 
these three cytokines, testosterone would cause a decrease in mRNA of IL-1 and 
TNF-α in the lacrimal glands of a mouse model of SS.(42) 
 
Previous studies evaluating sex hormone influence on glands of SS mainly are 
molecular in nature 
 
Studies looking at serum levels of hormones, RT-PCR analysis of hormone receptor 
mRNA, and DNA- microarray analysis abound,(50,83-88) but very little research has 
been directed toward the IHC analysis of MLSG biopsies of SS patients. The earliest 
mention of using IHC to evaluate sex hormone influence in salivary gland tissue of 
SS patients was by Kumagami and Onitsuka in 1993. They stained for the hormones 
estradiol, testosterone, and dihydrotestosterone in only (9) patients with secondary 
Sjѳ̈gren’s syndrome. Compared to controls, the SS patients showed more reactivity 
for the androgenic hormones. Unfortunately the controls were neither age nor sex 
matched.(89) In 1998, Onodera, and colleagues used IHC to analyze the estrogenic 
enzyme, aromatase in MLSG biopsies of SS patients of both sexes and varying 
ages. His study showed more aromatase activity in the SS patients compared to 
patients with other salivary gland pathoses.(90)  More recently, however, Spaan, et 
al localized the intracrine enzymes within the cytoplasm in SS patients and healthy 
controls.(81) 
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No previous IHC evaluation of the ER/AR ratio in sicca syndrome patients’ 
MLSG biopsies 
 
Several studies have mentioned the possibility of an interaction or a delicate balance 
between the seemingly opposing influences of androgens and estrogens in the 
exocrinopathy of SS. (54,71,81,91) To date no study utilizing an IHC evaluation of 
ER to AR ratio in a population of sicca syndrome patients has been reported. A 
comparison between these sex steroid hormone receptors to an age/sex matched 
control population is also lacking. The advantage of immunohistochemical (IHC) 
evaluation of biomarkers is that it allows for the anatomic localization of the marker 
at the tissue level (glandular) as well as at the cellular level within that tissue. With 
sex hormone receptors for example, IHC allows for the evaluation of where, within 
the gland, the cells that house the receptors are located, i.e. acini vs. ducts, as well 
as where, within the cells, the receptors are found, i.e. cytoplasm vs. nucleus. The 
intracrine formation of sex hormones at the cellular level, mentioned previously, 
makes this type of evaluation essential since each cell can potentially have its own 
level of sex hormone activity completely independent from the rest of the tissue.  
Additionally, a technique which uses homogenized tissue may miss circulating levels 
of pro-hormones that are within normal limits but  are inappropriately  processed at 
the target cell as has been suggested(54).  
 
In SS, IHC has been used to detect the hormones themselves, the receptors for the 
hormones, the steroidogenic enzymes involved in converting the precursor to the 
active hormone, and other downstream, surrogate, biomarkers which are influenced 
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by the hormones. By example, the use of a surrogate biomarker for androgen 
activity (CRISP-3) was expertly demonstrated in the 2007 study by Laine, Porola, 
and colleagues who combined both in vitro and in vivo techniques and utilized a 
combination of IHC, in situ hybridization, microarray analysis, ELISA and RT-PCR to 
convincingly show how SS is characterized by a “insufficient androgen effect” at the 
salivary gland level.(88) Recently, Spaan, et al compared the distribution of 
steroidogenic intracrine enzymes in the MLSGs of both SS patients and healthy 
controls using immunofluorescent IHC.(81) 
 
Limited information about IHC evaluation of normal expression of sex 
hormone receptors in normal human salivary glands 
 
There is very little baseline IHC data that demonstrates the expression of AR and/or 
ER in normal human salivary glands. Most of the existing data comes from studies 
evaluating the presence of these receptors in salivary gland neoplasms.(92-95) In 
1993, Laine, demonstrated the presence of AR in salivary tissue using IHC.(69) 
Valimaa, has shown that, although there are (2) isoforms of the estrogen receptor (α 
and β) the beta isoform predominates in the oral mucosa and salivary glands.(75) 
Yet there is no study, to date, which has used IHC to characterize the expression of 
ER to AR receptors in climacteric females. 
 
In the LG, MG, and SG androgens exert their effect through high-affinity, saturable, 
steroid-specific androgen receptors (AR) found within epithelial cells. Once 
activated, the monomeric hormone-receptor complex translocates to the nucleus, 
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and associates with the promoter region of an “androgen response element” (ARE) 
of specific target genes. Here it effects the transcription of various androgen-
dependent mRNA species.(55) 
  
An alternative signaling pathway for steroid receptors is being defined in which rapid 
cellular responses can be effected by plasma membrane bound AR, ER, and PR. 
(96,97)(96-98) 
 
Novel measurement of immunoreactivity in MLSG biopsies: The Allred Score 
  
In 1998, Allred, et al proposed an alternative method to the then, current “gold 
standard” of ligand binding assays (LBAs) used to assess the IHC ER status of 
breast cancer patients. The evaluation was essential to better predict which patients 
would benefit from adjuvant endocrine therapy.(99,100)The LBAs were technique 
sensitive, labor intensive, as well as expensive. IHC assessment of the receptor 
status proved to easier and had similar specificity and sensitivity. The “Allred Score” 
as it became known was validated, and has become widely accepted as a way to 
semi-quantitatively assessment of ER of a breast carcinoma. (101) It looks at the 
percentage of cells that are immunoreactive and assigns a “proportion score” (PS) 
on a scale of 0-5 (see figure). It then looks at the average intensity of the staining in 
those cells and assigns an “intensity score” (IS) on a scale of 0-3. The PS and IS are 
then added together to obtain the “total score” (TS), the Allred score. An Allred score 
of <3 is considered negative by medical pathologists. When introduced the intra- and 
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inter-reproducibility of the scoring was seen to be >90% in Allred’s laboratory.(99) 
There are no published studies in which the Allred score was used to assess sex 
hormone receptor in MLSG biopsies. This will be the first. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
 
Institutional  Review Board approval (Study #: 08-0989) to conduct studies on 
archived pathology specimens was obtained  for both the University of North 
Carolina, Chapel Hill (UNC-CH), and Carolina’s medical Center, Charlotte (CMC).  A 
search of the Oral & Maxillofacial Pathology Laboratory’s database for the last 3 
years yielded a potential cohort of patients whose tissue was submitted for 
histomorphometric analysis as part of the diagnostic work-up for primary Sjögren’s 
syndrome (SS) (N=47). 
 
Patient selection 
Sicca Specimens 
Tissue used in this study consisted of excess archival minor labial salivary gland 
(MLSG) tissue submitted from a single institution (CMC).  Pertinent medical 
information about each specimen was obtained through chart review of medical 
records at CMC.  Information gathered included:  patient age; race; focus score (FS) 
from MLSG biopsies; smoking history; subjective ocular symptoms; Shirmer’s test 
results; objective oral  dryness; hormone replacement therapy (HRT)history; history 
of systemic steroid use; duration of symptoms; other medical conditions; previous 
treatments rendered; and treatment response. The “sicca” patients were further 
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divided into two groups: those with a FS ≥ 1 (group A); and those with a FS<1 (group 
B). 
Control Specimens 
Control specimen (group C) tissue was obtained from the tissue archives of the Oral 
& Maxillofacial Pathology Laboratory at UNC- CH.  The control specimens were 
tissue samples previously submitted from peri- and post-menopausal females who 
had MLSG tissue incidentally included in their specimens, and had no reported 
history of xerostomia. A database with the patients’ information was created.  
Subsequently all paraffin blocks were de-identified regarding accession numbers 
from UNC-CH and assigned a study number that corresponded to the one in the 
database and was different from the accession number.  The data base is kept in a 
password-protected secure server behind a firewall at UNC School of Dentistry’s 
Research server.  Only two of the investigators have access to the database. 
Inclusion Criteria 
SS Specimens  
All specimens were minor labial salivary gland biopsies (MLSG) of peri- and post-
menopausal females. Only specimens from patients who exhibited 3 of the5 
diagnostic criteria for primary SS established by the joint American European 
consensus of 1996, and revised in 2001 were included (24). All specimens came 
from patients who had complaints of dry eyes and dry mouth, and  a negative blood 
test for anti- nuclear antibodies (ANA), SS A/Ro and SS B/La. (N= 28) 
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Control specimens 
All specimens were from patients who were peri - or post-menopausal females who 
had incidental findings of MLSG tissue within their specimens submitted for other 
reasons besides salivary gland pathosis.  At least 2 mm2 of gland parenchyma had 
to be included in the specimen. (N=8) 
Exclusion Criteria 
Sicca Specimens 
Only specimens from the clinic at CMC were included in these groups. Any 
specimen from a patient who had evidence of anti-nuclear antibody test (ANA) in 
their serum was excluded.  Patients who had secondary SS were not included in the 
study. Specimens obtained from any other intra-oral location besides the lower lip 
were excluded as well. 
Control Specimens 
Submitted MLSG tissue could not contain neoplasms, either benign or malignant, 
amyloidosis, or granulomatous inflammation. If the area of the gland parenchyma in 
the specimen measured less than 2 mm2 the specimen was excluded.  Any 
specimens from intraoral locations besides the lower lip were likewise excluded. 
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Immunohistochemical (IHC) Staining 
Tissue specimens were formalin-fixed paraffin-embedded (FFPE) MLSG biopsies. 
Seven micrometer sections were cut and mounted on plus-coated glass slides.  IHC 
was performed at the APTCL (Anatomical Pathology Translational Core Lab) at 
UNC-CH according to the following protocol. 
Antibodies:  
Rabbit polyclonal anti-Androgen ReceptorPG21 antibody (Cat# 06-680) was 
purchased from Chemicon® International Company/Millipore Corporation, Temecula 
CA 92590. Mouse monoclonal anti- human Estrogen receptor α antibody (M7047), 
clone 1D5 was from Dako North America, Inc. Carpinteria, CA 93013. Rabbit 
polyclonal anti-Estrogen Receptor-beta Ready to use antibody (Cat#AR385-5R) was 
purchased from Biogenex 4600 Norris Canyon Rd. San Ramon, CA Mouse 
monoclonal anti-Human Progesterone receptor (NCL-PGR-312), clone 16 from 
(Leica Microsystems Inc.  Norwell MA 02061) 
Automated detection: 
 Estrogen Receptor (ER-α) and progesterone Receptor (PR) stains were carried out 
in the Bond Autostainer (Leica Microsystems Inc. Norwell MA 02061) according to 
the manufacturer’s IHC protocol. Briefly, slides were de-waxed in Bond Dewax 
solution (AR9222) and hydrated in Bond Wash solution (AR9590). Antigen retrieval 
was performed for 30 min at 100ºC in Bond-Epitope Retrieval solution 1(pH-6.0) or 
solution 2 (pH-9.0) for PR and ER respectively.  Slides were incubated with the 
appropriately diluted primary antibodies for 2h (EGFR). Antibody detection was 
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performed using the Bond Polymer Refine Detection System (DS9800). Stained 
slides were dehydrated and cover slipped. 
Estrogen receptor- β (ER- β) was carried out in the DAKO Autostainer according to 
the Dako Auto-Envision IHC protocol. Steam Antigen retrieval was performed for 30 
min in DAKO Target Retrieval Solution pH-6.0 (Cat.#S2369) 30 min.  
Antibody detection was performed using the DAKO Envision Labelled Polymer HRP 
Rabbit (Cat.#K4003).  Chromogen      2 min. Innovex DAB (Cat.# NB314SBD). 
Counterstained stained slides in Hematoxylin DAKO 30 sec.(Cat.# S3309). Bluing 
30 secs. Stained slides were dehydrated and cover slipped. 
Manual detection: 
Androgen receptor (AR) stain was conducted manually using Vectastain ABC Rabbit 
kit Mouse detection system according to manufacturer's instruction (Vector 
laboratories, INC Burlingame, CA94010). Heat induced antigen retrieval was carried 
at pH -6.0  using Dako Cytomation Target Retrieval Solution(S1699) for 30 min. 
Slides were incubated overnight at 4ºC with the primary antibody. 
Positive and Negative Controls 
Appropriate positive controls were utilized for each of the antibodies reacted. Human 
prostate tissue was used for the AR antibody, and human breast tissue was used for 
the ERs and PR antibodies.  Sections of MLSG tissue from each of the three groups 
were incubated with the appropriate serum that did not contain the primary antibody 
for the negative controls. 
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Histomorphometry 
Focus scores (FS) were determined prior to the start of the study by two, Board-
Certified Oral & Maxillofacial Pathologists (VM,RP) experienced in 
histomorphometric analysis. MLSG specimens were sectioned, mounted on glass 
slides, stained with hematoxylin & eosin, and visualized with standard light 
microscopy using an Olympus BX41 stereoscopic microscope (Olympus America 
Inc.,Center Valley, PA).The total area of glandular parenchyma was measured using 
a reticule within the ocular of the microscope. Lymphocytic “foci” were then counted 
within that area. A focus of lymphocytes is determined to be an aggregation of 50 or 
more lymphocytes adjacent to viable parenchyma of salivary gland.  The “focus 
score” was then calculated according to the following formula:  
 
Focus Score = (# of Foci X 4) / Area 
 
Analysis of IHC 
All slides were examined using standard light microscopy using an Olympus BX41 
stereoscopic microscope (Olympus America Inc.,Center Valley, PA). The 
immunohistochemical signal was scored using a modified version of the “Allred 
Score”(99), which is a semi-quantitative tool originally developed to evaluate 
hormone receptor immunoreactivity in breast cancer specimens. It is a two-part 
assessment that looks at the number of cells that are staining, and also the intensity 
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of the staining in those cells. In the original Allred scoring system, a “Proportion 
score” in a scale of 0-5, corresponding to increasing percentages of cells reacting is 
added to the “intensity score” in a scale of 0-3 which assesses the intensity of the 
immunoreactivity of the cells. The resulting sum total of proportion and intensity 
scores gives the final “Allred Score” of 0-8 (excluding 1).  See Table1A and B  and  
Figure 1 
Table 1A: Table showing the Allred Score proportion score and its corresponding 
percentage of cells. 
Proportion 
Score 
Percentage of 
cells  
0 0 
1 <1 
2 1-10 
3 11-33 
4 34-66 
5 67-100 
 
Table 1B: Table showing the Allred Score intensity score and its corresponding 
reactivity. 
 
 
 
 
 
 
 
 
 
Intensity 
Score 
Reactivity 
0 None 
1 Weak 
2 Moderate 
3 Strong 
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Figure 1 : Illustration of the Allred score, depicting  visually, the immunoreactivity of 
tissue. (99) 
 
A “Modified Allred score” was created in the current study (Figure 2).  It consists of 
the same intensity scale , but the proportion scale is reduced from 0-5 to 1-4, 
yielding a total score in the range of 1-7. This allows for a more equal distribution of 
the percentages within each proportion level and for more consistent scoring of 
specimens, especially at the lower end of the scale, where subtle differences tended 
to be more common. 
 
Table 2: Table showing a modified version of the Allred Score with compression of 
all values less than 10% of the proportion score being represented by a score of 1.  
The same intensity score is used. 
 
 
 
 
 
 
Intensity 
Score 
Reactivity 
0 None 
1 Weak 
2 Moderate 
3 Strong 
Proportion 
Score 
Percentage of 
cells  
1 <10 
2 11-33 
3 34-66 
4 67-100 
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Statistical Analysis 
All data was collected and entered into Excel spreadsheets. Statistical analysis of 
the data was performed. Comparisons between the three groups’ ages were 
performed using the Kruskal-Wallis test.  Comparisons of the ratios ER-α and ER-β 
to AR in each of the three groups were performed using the Kruskal-Wallis test 
(SPSS v.16 GP 2007; SPSS Inc., Chicago, IL).  Due to sample size of group B and 
C, statistical testing of the reactivity patterns  of each receptor antibody was only 
performed within group A. The intensity and proportion stains were modeled 
separately using a proportional odds model with cumulative logits and a general 
estimating equation method for ordinal categorical data. 
 
Photomicrography 
Photomicrographs of the specimens  were captured using an Olympus DP 70 digital 
camera mounted atop a Olympus BX41 stereoscopic microscope (Olympus America 
Inc.,Center Valley, PA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Patient Demographics 
The focus scores, age and race of the patients are summarized in table 1. Patients 
were divided into three groups based on FS: group A had FS ≥1 (n=20) ; group B 
FS<1 (n=8); and group C were controls (n=8). The ranges of FS were: A= 1.0-9.9; 
B=0.30-0.80. 
The age ranges of each group were: A= 34-79yrs; SS-= 46-69yrs; and CG= 42-81. 
The mean age for each group was: SS+= 60.3yrs (SD=14.1); SS-= 53.9yrs 
(SD=8.8); and CG=56.6 (SD= 13.8). The unpaired t-Test was utilized to show there 
was no statistically significant difference in the average ages of the groups (p=0.34). 
Of the sicca patients: two were African American (A=1, B=1), all others were 
Caucasians; four were current smokers, two from groups A and B, respectively.  See 
Table 3 
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Table 3: Demographic data showing age, race and focus score for the three 
experimental groups. Group A has FS ≥1, group B has FS<1, and group C is the 
control group. (p=0.34) 
 
 
Hormone Receptor Immunoreactivity 
The results for the statistical analysis of the receptor immunoreactivity are 
summarized in Table 4. Based on the intensity of immunohistochemical reactivity of 
MLSG of patients from group A, and controlling for subcellular location, a 
proportional odds model with cumulative logits using a general estimating equation 
method for ordinal categorical data showed that the likelihood of having greater 
intensity of AR reactivity is 37.3 times higher than reactivity to ER-α, and 7.71 times 
higher than reactivity to ER-β (i.e. AR> ER-β> ER-α) (p<0.001). See Table 4A 
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Table 4A: Intensity of immunoreactivity in the SS group (group A) as a function of 
receptor type. When controlling for subcellular location, AR is 37.7 times more likely 
to be more intense than ER-α, and 7.7 times more likely than ER-β. 
 
Contrast Predicted 
OR 
P-Value 
AR vs. 
ER 
37.33 < 0.0001 
AR vs. 
ERB 
7.71 < 0.0001 
ERB vs. 
ER 
4.84 < 0.0001 
 
By the same method of assessing antibody reactivity, the, likelihood of having a 
higher proportion of cells that react to AR is 92.5 times higher than ER-α, and 187 
times higher for ER-β when controlling for subcellular location (i.e. AR> ER-α > ER-
β) (p<0.001), and there is a 4.8 times higher likelihood of having a greater intensity 
of cells that react with ER-β compared to ER (p<0.01) and a twice the likelihood of 
having a higher proportion of cells that react to ER-α than to ER-β (p=0.02). See 
Table 4B 
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Table 4B: Proportion of cells immunoreacting in the SS group (group A) as a 
function of receptor type. When controlling for subcellular location, AR is 92.49 times 
more likely to have a greater proportion of cells immunoreacting compared to ER-α, 
and 186.77 times more likely than ER-β; ER-α is 2.02 times more likely to  to have a 
greater proportion than ER-β. 
 
Contrast Predicted 
OR 
P-Value 
AR vs. ER 92.49 < 0.0001 
AR vs. ERB 186.77 < 0.0001 
ER vs. ERB 2.02 0.0167 
 
Hormone Receptor Distribution  
Androgen receptors 
The most intense AR immunoreactivity score was observed in both the nuclei of the 
ductal cells (Mdn=7, IQR= 0) and the nuclei of the acinar cells (Mdn=7, IQR= 0). See 
Figure 2A and B.  
Figure 2A: Androgen receptor immunoreactivity in the ductal nuclei (arrow) 
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Figure 2B:  Androgen receptor immunoreactivity in the acinar nuclei (arrows). 
 
The ductal cell cytoplasm, although noticeably reactive, was less intense with a 
median score of 6 (IQR= 0), and the acinar cytoplasm was the least immunoreactive 
with a median score of 4 (IQR= 0). See Results Figure 2A and B. This distribution of 
reactivity was independent of the FS. The cells whose nuclei stained most intensely 
were at the periphery of the acini and mostly abluminal to the ducts. In these 
locations all of the cells were immunoreactive.  
The cytoplasm of serous demilunes surrounding mucous acini was more 
immunoreactive for ER-α than for AR.  See Figure 3A and B. 
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Figure 3: Immunoreactivity of receptor antibodies within serous demilunes of the 
MLSG.  
A: Weak AR immunoreactivity in the acinar cytoplasm except in the serous 
demilunes where moderate reactivity was seen (arrows). 
 
 
 
B: Stronger ER-α immunoreactivity in the serous demilunes and, as with AR, a 
similar lack of reactivity in the other acinar cytoplasm (arrows). 
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Estrogen-α Receptors 
All groups showed weak reactivity to ER-α antibody in all but the cytoplasm of the 
ductal cells,  median score of 5 with an IQR of 1. See Figure 4 A and B.  
 Figure 4: ER-α immunoreactivity in cytoplasm of the ductal and acinar cells 
 
A: Moderate ER-α immunoreactivity in the cytoplasm of ductal cells (arrows) 
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B: Weak ER-α immunoreactivity in the cytoplasm of acinar cells (arrows). 
 
 
As can been seen in figure 4, we observed intense globular areas of cytoplasmic 
immunoreactivity adjacent to the nuclei in both acinar and ductal cells in all three 
groups.  
Figure 5: High power (40x) view of image seen in figure 4A showing globular areas 
of cytoplasmic immunoreactivity (arrow). 
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Inspissated pools of saliva were highly immunoreactive to ER-α compared to the 
other receptors in groups A and B. This phenomenon was not observed in the 
mucoceles from control patients. See Results Figure 6 A-D. 
 
Figure 6:  ER-α  immunoreactivity in mucous pools within the SS group (group 
A)compared to extravasated mucus in the control group (group C), and lack of 
immunoreactivity with the other receptor antibodies. 
 
6A: Strong ER-α immunoreactivity in the inspissated mucus (arrows). 
 
 
 
6B: Lack of ER-α immunoreactivity in the extravasated mucus of a mucocele 
(asterisk). 
 
 
* 
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6C:  Lack of AR immunoreactivity in the inspissated mucus (arrows). 
 
 
 
 
 
6D: Lack of ER-β immunoreactivity in the inspissated mucus (arrow). 
 
 
 
 
 
Estrogen-β Receptors  
All groups revealed intense ER-β immunoreactivity. The ductal cells’ nuclei had a 
median score of 6 with an IQR of 0, and in the nuclei of the acinar cells had a 
median score of 5, with an IQR of 1.  Only weak antibody staining was observed in 
the cytoplasm of the acinar and ductal cells. Intense nuclear staining was also seen 
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diffusely throughout the parenchyma of the gland and in a subset of cells at the 
periphery of acini and abluminally in ducts.  See Figure 7. 
Figure 7: ER- β immunoreactivity in the different experimental groups showing 
viable intensity and number of cells reacting, but consistently nuclear in its location. 
 
A:  Group A showing strong but inconsistent nuclear reactivity 
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B:  Group B showing moderately intense immunoreactivity in subsets of cells. The 
ductal nuclei appear to be in the majority of cells reacting. Reactivity is moderately 
intense 
 
C: Group C showing moderately intense but more variable proportion of cells 
reacting. Still, strictly a nuclear pattern. 
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Progesterone receptors  
PR immunoreactivity was observed in only two cases: one in group A; and one in 
group C. In both instances, reactivity was noted only in the acinar cytoplasm. See 
Figure 8. 
Figure 8: Isolated cases of PR immunoreactivity. 
 
8A: In Group A showing weak, diffuse acinar cytoplasmic reactivity (arrows). 
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8B: In Group C showing very weak variable immunoreactivity in a subset of cells.
 
Comparison of ratios of ER to AR by group (Group A vs. Group B vs. Group C) 
When the ratio of ER to AR is compared, there is no statistically significant 
difference noted between the groups. No difference in this trend is noted whether 
ER-α or ER-β is used in the ratio. Although differences do exist, none reach 
statistical significance. See Table 5A and B. 
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Table 5A: Comparison of ER-α/AR as a function of FS. No statistically significant 
comparisons were identified 
 ER-
α/AR 
NA 
ER-
α/AR 
CA 
ER-
α/AR 
DN 
ER-
α/AR 
DC 
Group A 0.250 0.439 0.458 0.793 
Group B 0.226 0.477 0.415 0.810 
Group C 0.220 0.523 0.635 0.818 
 P-Value* 0.9958 0.2965 0.2050 0.9073 
       *Kruskal-Wallis test 
5B: Comparison of ER-β/AR as a function of FS. No statistically significant 
comparisons were identified 
 ER-
β/AR 
NA 
ER-
β/AR 
CA 
ER-
β/AR 
DN 
ER-
β/AR 
DC 
Group A 0.639 0.297 0.877 0.314 
Group B 0.726 0.310 0.882 0.262 
Group C 0.709 0.221 0.929 0.191 
 P-Value* 0.5040 0.1039 0.3646 0.0522 
       *Kruskal-Wallis test 
Other areas of staining within the glands 
The lymphoplasmacytic foci within the glands of both group A and group B reacted 
with AR, ER-β, and to a lesser extent, ER-α.  Within these foci, the plasma cells 
were the more immunoreactive cell type, and were mainly stained by AR and to a 
lesser extent ER-β. In control patients, who also had lymphoplasmacytic infiltrates, 
were observed to be overall less intensely reactive to the receptor antibodies 
compared to the sicca patients.  See Figure 9. 
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Figure 9: Differences in immunoreactivity of hormone receptor antibodies in 
inflammatory infiltrates of sicca patients compared to controls 
9A: Comparison of AR, ER- α, and ER-β in sicca patient specimens’ 
lymphoplasmacytic infiltrates. Note the relatively intense reactivity of all the stains 
with AR > ER-β > ER- α. 
AR      ER-β     ER-α  
     
 
9B: : Comparison of AR, ER- α, and ER-β in control patient specimens inflammatory 
cell infiltrates. Note the reduction in intensity of all the antibodies with ER-β > AR > 
ER- α. 
 
 AR    ER-β    ER-α 
           
 
 
 
 
 
 
 
DISCUSSION 
 
In this pilot study we analyzed described a cohort of perimenopausal women who 
were being evaluated for SS. All of the women met many of the diagnostic criteria for 
SS except for serologic evidence of SS-A or SS-B in their blood analysis. A MLSG 
biopsy was indicated to make the final diagnosis.  Twenty of the women had a FS≥1 
in their MLSG biopsy (group A) and therefore were confirmed to have primary SS. 
Eight other women in this group had a FS<1 negating the diagnosis of SS (group B), 
despite meeting many of the other diagnostic criteria. We examined the expression 
of the sex steroid hormones receptors for differences between these two groups. In 
addition, we compared the receptor expression in MLSGs of eight sex- age-matched 
patients who were not being evaluated for SS-like symptoms (group C).  
Estrogens are pro-inflammatory while androgens ameliorate 
inflammation.(35,102,103) We hypothesized that SS is not mediated only by a 
decrease in systemic and local androgenic influence as some authors have 
proposed(2); nor is it precipitated by a local, intracrine overproduction of estrogen. 
We hypothesized also that  the balance between the sex steroid hormones’ 
influence is altered, contributing to a pro-inflammatory environment in genetically 
susceptible individuals. We propose that group A will exhibit a differentially 
increased expression of ER compared to group B, who should have less of a 
difference in their ratio of ER to AR. Finally, group C should have relatively more AR 
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expression compared to the other two groups. By comparing the ratio of estrogen 
receptor expression to the androgen receptor expression (ER/AR) between the 
groups, we anticipate finding an increasing trend in this ratio as FS increases. 
 
This hypothesis has its basis in the fact that AR and ER are auto-regulated. (55,104) 
This means that the presence of their ligand causes an upregulation of the receptor 
protein itself in addition to other response proteins. By using the receptor protein 
expression as our biomarker rather than the presence or absence of the hormones 
themselves, prevents the erroneous interpretation that measuring hormone level 
reactivity may foster. The presence of hormone does not necessarily mean it is 
effecting a change in the cellular functions. Furthermore evaluating “hormone 
response biomarkers” (CRISP-3, LIV-1) does not account for the possibility of ligand 
independent stimulation of receptors leading to receptor response protein 
expression. Additionally, receptor protein expression is pivotal in reflecting the milieu 
of the cells’ intracrine status. For example, if there is an estrogenic influence 
enhancing aromatase activity, there will be a consequent increase in the expression 
of ERs and PRs (90). On the other hand, if there is an androgenic environment, AR 
protein expression will occur. 
 While our results show that antibodies for AR, ER-α, ER-β all showed appreciable 
amounts of immunoreactivity in the glandular parenchyma as well as variable 
immunostaining in adjacent structures, the three comparison groups  did not show 
any statistically significant difference in their ratio of ER to AR. Furthermore, PR 
immunoreactivity was seen to be virtually non-existent.    
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In the SS group, however, a significant trend became apparent: AR had the greatest 
odds of being reactive regardless of location in the gland or subcellular 
compartment. For decades it has been proposed that SS is driven by an overall 
androgen deficiency. (2,8,71,91) More recently, however, tissue-level androgen and 
DHEA deficiencies have been proposed as a mechanism for the glandular 
destruction seen in SS.(54,81,88) Results of the present study demonstrate that the 
predominant presence of AR over the other steroid hormone receptors in SS 
patients indicates that androgens are present, at least at the tissue and cellular level, 
in adequate concentrations in these patients as well. 
 
There are several reasons why no statistically significant difference was seen in the 
reactivity patterns between the groups.  Most importantly, sample size was a 
significant limiting factor in this study, raising the possibility of introducing a type II 
statistical error (false negative). Our database only yielded twenty-eight patients in 
whom the inclusion criteria were met. Achieving statistical significance was not 
possible considering the sample sizes and the number of comparisons attempted. 
Due to these statistical limitations, we were only able to analyze the SS group for 
trends, and, even within this group, there were insufficient numbers of patients to be 
able to analyze each subcellular location for trends involving each receptor protein. 
 
 The data did not support the hypothesis as stated, and this could have been caused 
by several factors. Our study groups were shown to be similar in terms of age as 
proven by a p value= 0.34. However, the groups may not have differed significantly 
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in terms of the following clinical parameters: salivary flow, HRT history, corticosteroid 
use. With a larger sample size these factors could be controlled for.  
 
The main differentiation among the sicca patients was based on FS. It might prove 
useful in the future to test the inter-observer reliability of the Oral Pathologists (VM 
and RP) to determine if FS values are reproducible.  
 
Furthermore, the control group sample size was small and was based on a 
convenience sampling from the tissue archives. The former was driven by the fact 
that the population age of our study very few MLSG biopsies are performed that 
yield glandular tissue that could not be excluded for other reasons, such as 
significant morbidities associated with them. For the purposes of this study, we did 
not have enough preliminary data to merit enrolling age-, sex-matched control 
subjects with stricter inclusionary and exclusionary criteria. Therefore, the present 
control group, being represented by mainly traumatically motivated specimen 
collection may not be optimal for comparison with our sicca patient sample. Both 
have inflammatory cell infiltrates: one is autoimmune induced; the other reactive in 
nature. 
 
Our choice of sex steroid receptors could have been specious; although at the 
genesis of this project it did not seem so. Controversy exists as to whether the 
autoimmune inflammatory infiltrates in the main exocrine glands affected by SS were 
mediated by androgens or estrogens. Studies investigating serum levels of gonadal 
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and adrenal hormones and prohormones, respectively, showed that SS was a 
hormone mediated disease, (3,8,51,66,71,105). However, it was Labrie, et al who 
agreed that SS was hormone mediated, but its pathogenesis may lie at the cellular 
level of the affected glands.(47,106) Several studies had previously shown that the 
sex hormones themselves could be demonstrated in the salivary and ocular 
glands.(89,93) Furthermore, intracrine, steroidogenic enzymes have been 
demonstrated in both salivary and ocular tissues. (65,90)Laine, et al proved that the 
effects of androgens’ influence were being rendered via androgen response 
proteins, like CRISP-3, although at lower levels, hypothesizing that an androgen 
deficiency might be the inciting factor.(88)  In summary, past studies have shown 
that, despite a general systemic deficiency of androgens and estrogens: 1)the 
receptor ligand was proven to be present; 2)the intracrine machinery to produce this 
ligand was demonstrated; and 3) the effects of ligand binding to the receptor were 
shown. However, no studies addressed the expression or localization of the 
receptor.  
 
Although all of these receptors have been shown to be expressed in the human 
salivary gland, no study ever established what the normal expression, distribution, or 
subcellular localization of these receptors was in formalin fixed, paraffin embedded 
archival tissue. Moreover, the studies that exist use various assays to evaluate the 
presence of the receptor proteins and do not give consistent results.(69,93-95,107-
110) Other studies discussed receptor protein expression in the context of salivary 
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gland neoplasms but did not compare this expression pattern to normal expression 
patterns.(92,111,112) 
 
Another reason may be that both AR and ER, in the presence of their ligand at 
physiologic concentrations, reach a steady state between their activated form in the 
nucleus and their inactive cytoplasmic form. Once that threshold is reached only 
minor variations may occur unless the ligand is completely withdrawn (113,114)Even 
though innumerable copies of the mRNA can be made by a transcription factor (i.e. 
activated receptor), there are only a finite number of estrogen response elements 
(EREs) and  androgen response elements (AREs) in the DNA with which the 
receptors can directly interact. 
 
Another explanation for our results may be methodological. Immunohistochemistry 
has many benefits over ligand binding assays of the past and molecular assays 
used in more recent studies. (113,115)Most importantly, the preservation of the 
tissue and cellular architecture allows more accurate assessment of receptor 
distribution within the cells of interest. However, the IHC technique also has 
technical pitfalls that may falsely mask significant trends. (113,116)Although the 
antibodies used are all commercially available and had been previously optimized by 
our laboratory for use on formalin-fixed paraffin embedded (FFPE) tissue, there can 
be a progressive loss of antigenicity of ERs in the tissue as time elapses after 
sectioning.(116-118) This technical detail was not known at the time that multiple 
levels of the archival specimens were cut in preparation for this and future studies. In 
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the process, much of the sample tissue was depleted in the paraffin blocks. If all of 
the receptors were equally affected by this decrease in immunoreactivity, the ratios 
between them would be intact, albeit less intense. If the ERs are preferentially 
affected, then a very significant negative bias is could potentially be introduced.  
Furthermore, the subcellular location of the receptors can preferentially make them 
more or less susceptible to degradation with tissue processing. (119) Time from 
excision to fixation, type of fixative, duration of fixation, and section thickness can all 
impact the immunoreactivity and interpretation of the receptor protein.(116) Estrogen 
receptors, being housed in the cytoplasm, are particularly vulnerable to tissue 
processing artifacts.  
 
The methodology for assessing the reactivity can introduce another variable and 
potential bias. In this study we attempted to adapt the “Allred Score” as a semi-
quantitative evaluation of an otherwise ordinal grading scale. The “Allred score” is 
one of several visual assessment tools used to evaluate immunoreactivity. Others 
include: the subjective “Gestalt” method where one visually assigns a value of 0 
(non-reactive), 1+ (weak),2+(moderate), 3+ (strong); the “H score”, which includes 
measures of the percentage of positive nuclei with intensity of the staining;  and 
video image analysis using mean optical density (MOD) of the 
staining.(113,120,121) All of these methods have unique strengths and weaknesses 
depending on the situations they are applied. The “Allred score” is specifically used 
to determine ER/PR immunoreactivity in breast carcinomas to assess the estrogen 
sensitivity of the tumor and its responsiveness to endocrine therapy (Tamoxifen™). 
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In this method, a “proportion score” (PS), which is a survey of the percentage of 
positively staining cells, is combined with a score for the intensity of the 
immunostaining (intensity score (IS)). It yields a range of possible scores of 0-8, with 
the exclusion of a score of 1.(99,100)  Although the “Allred score” is designed to 
appreciate the heterogeneity of the reactivity patterns in breast cancer specimens, it 
begins to lose its sensitivity when attempting to assess subtle variations in 
immunoreactivity, especially when the proportion score and the intensity diverge 
equally. For example, if a specimen has 34% of the cells reacting (PS=3), and that 
reactivity is strong (IS=3), the resultant Allred Score= 6. Conversely, in a different 
specimen has 100% of the cells reacting (PS=5), but the reactivity is only weak 
(IS=1), this specimen also has an Allred score =6 even though the immunoreactive 
patterns of the two specimens differ greatly. Furthermore, in surgical pathology, any 
“Allred score” <3 is considered to be negative. It was not designed for “shades of 
gray”, but more for accurate assessment of grossly positive vs. negative.  
 
Upon its introduction, the Allred score was shown to be reproducible when utilized 
by different observers. In the current study, only one observer (JR) scored the IHC 
immunoreactivity. At the time of the experiment, no previous studies provided insight 
into the trends that might emerge. Because of this, the data collected was assumed 
to be reliable.  A possible source of error in the data may have been a lack of intra-
observer reliability. In the future, it would be prudent to perform an intra-observer 
reliability assessment. 
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The use of a ratio of hormone receptors to explore the delicate balance that may 
exist between the pro-inflammatory influences of the estrogens and the anti-
inflammatory influences of the androgens. It was hoped that the previously proven 
androgen deficiency combined with the increasing estrogenic environment of the 
glands would easily become apparent. Unfortunately, the use of ratios may mask 
significant trends. This would be particularly true if there were significant, but 
proportional changes in both the numerator and the denominator. 
 
The patterns of the receptor proteins’ in our study are intriguing. As discussed 
above, AR reactivity was significantly more common than any of the other receptor 
proteins. We observed intense AR immunoreactivity in most of the nuclei of the 
acinar cells and good reactivity, but less reactivity in the cytoplasm of the acini 
compared to the nuclei. The cytoplasmic reactivity highlighted the serous demilunes. 
As seen in figure 3B.  
 
This result is consistent with a previous study of AR localization in the salivary 
glands of humans by Laine, et al.(69) Alternatively, our results differ with a later 
study by the same group.  In 2007, Laine’s group found that an androgen response 
protein, crisp-3, was polarized to the area of serous demilunes in healthy controls, 
but lost this polarization in SS patients.(88) In contrast to this finding, our study 
showed that despite the presence of SS, AR reactivity seemed more intense in the 
cytoplasm of the serous demilunes.  In the ductal cells, a similar pattern emerged, 
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although the ductal cell cytoplasm and nuclei were both quite immunoreactive. As 
seen in figure 2A. 
 
All of the sex steroid hormones are ligand-binding transcription factors that are 
produced in the cytoplasm and then either reside in the cytosol in an inactive state, 
as is the case with AR, or are shuttled into the nucleus prior to interacting with their 
hormone ligand, as seen with ER and PR. (122)If there is cytoplasmic AR reactivity, 
this is evidence of the presence of the receptor, however it is unbounded, inactive, 
and not resulting in DNA transcription (119,123,123). In the present study, the nuclei 
of acinar cells exhibited the greatest AR reactivity, indicating effective transcription. 
In the ductal cells, however, it appears that either no hormone is available or that it is 
not causing active transcription via the classic receptor pathway. 
 
The reaction pattern of ER-β revealed an almost exclusive nuclear reactivity which 
decorated the periphery of ducts and to a lesser degree, acini. Architecturally it was 
difficult to determine if the acinar reactivity was in mucocytes, myoepithelial cells, or 
a combination of both. As seen in figure 7A.  This pattern was seen throughout the 
entire specimen, although, in areas of immunoreactivity, not all of the cells 
expressed ER-β positivity. Very minimal cytoplasmic reactivity was noted, whether in 
proportion of cells reacting or in intensity. The almost exclusive nuclear reactivity is 
consistent with the findings of Valimaa, et al in 2004.(75) In the present study, 
consistent immunoreactivity of nuclei localized to the periphery of the acini and 
ducts, in the position often occupied by myoepithelial cells, might indicate reactivity 
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of these cells. Further studies, including possible double labeling of these cells may 
answer that question. 
 
When ER-α staining is observed, there is a distinct reduction in intensity of the tissue 
reactivity. ER-α was found diffusely staining the cytoplasm of the ductal cells, and to 
lesser extent acinar cells. An interesting observation, unique to ER- α, was that, 
within the cytoplasm immediately adjacent to the nucleus, were noted numerous 
focally intense globular areas of immunoreactivity (Figure 5). This phenomenon was 
seen in a number of specimens in both acinar and ductal cells, and in all groups 
compared. No mention of this type of staining could be found in the literature, but it 
is reminiscent of perinuclear, “Golgi dot” pattern seen with CD30 reactivity in 
Hodgkin lymphoma and the CD117 (C-kit) reactivity in gastrointestinal stromal 
tumors (GISTs). This pattern may indicate a derangement in the post translational 
maturation and subsequent sequestration within the Golgi apparatus of the ER-α 
receptor protein. (124) 
 
 Another interesting finding is the intense immunoreactivity of ER-α in inspissated 
mucous.  This was not seen with the other receptor antibodies. It was not seen in the 
extravasated mucous of the mucocele patients in the control group. Spaan, et al 
recently demonstrated that there is an intracellular architecture to the intracrine 
enzymes involved in processing DHEA-S to the active hormones, in which 
aromatase was preferentially located near the apical pole of the acinar cells.(81) 
Aromatase is the enzyme needed to catalyze the conversion of testosterone to 
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estradiol. Porola also has shown that SS patients have slightly higher concentrations 
of salivary estrogen.(54) One could conceive of a process where aromatase 
catalyzes the conversion of testosterone to estradiol and then the estradiol is 
secreted with the salivary mucins. Moreover, if there is nascent estradiol in excess, 
like in a SS patient, this may bind the cytoplasmic ER and both could then be found 
in the saliva as well. There has been no mention in the literature of transport of 
hormone receptor protein out of the cell, so the reason and significance of this 
finding remains to be explained. 
Our study reveals immunoreactivity with ER-α contrary to previous studies. In 1992, 
Ojanotko-Harri, et al found only AR in sections of gingival and buccal 
mucosa.(108)In 2000, Leimola-Virtanen, et al demonstrated ER expression in 
mucosa and salivary gland only by RT-PCR but was not able to demonstrate its 
expression by IHC. It is assumed that both of these studies would have used 
antibodies for ER-α protein. The 1992 study was prior to the discovery of ER-β in 
1996, and Leimola-Virtanen did not state which ER antibody they used. By 2000, 
however, even though ER-β had been discovered, there may not have been an 
antibody for it commercially available. Moreover, Valimaa, in 2004 stated definitively 
that ER-β was the only ER found in human oral buccal and gingival epithelium or in 
human salivary glands.  Could it be that our ER-α  reactivity is artifactual? Evidence 
in support of this possibly lies in the lack of immunoreactivity to PR in all but two of 
our specimens. In both cases, however, higher cytoplasmic reactivity of ER-α was 
seen when compared to other specimens. 
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In the breast, it is well documented that PR is under estrogenic control. 
(114,125,126) Progesterone receptor expression indicates that the stimulation of ER 
by its hormone ligand has resulted in transcription of the DNA to induce PR 
expression. In the salivary glands, only Ozono showed evidence for PR expression 
and stated that it was exclusively found in cells that also contained estrogen and 
progesterone hormones in their cytoplasm despite the variable numbers of PR + 
cells. (93) In breast cancer patients ER/PR expression is a useful prognostic 
indicator. (127) ER+/PR+ tumors convey a favorable prognosis, and tumors that 
express neither receptor do not. Ironically, a tumor can express PR in the absence 
of ER and this still confers a favorable prognosis due to the inter dependence of PR 
on ER. (126) Considering this, it is conceivable that a cell can be ER+ and yet PR- . 
This may explain our results showing a variable and inconsistent PR 
immunoreactivity. 
 
Sjögren syndrome is characterized by lympho-plasmacytic infiltrates into the 
parenchyma of salivary and ocular glands.(128)  The inflammatory cell infiltrates in 
the specimens in this study were commonly found to be immunoreactive for AR, ER-
β, and ER-α in a decreasing order of intensity. There were variable patterns 
depending on the receptor, the cell type reacting, as well as the source of the 
inflammation. Androgen receptor reactivity was the most intense, and highlighted 
numerous plasma cells. This reactivity was seen mainly in the cytoplasm, but this 
may be due to the fact that plasma cells have abundant visible cytoplasm on tissue 
sections compared to lymphocytes. This finding is supported by others who have 
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demonstrated hormone receptors being expressed in immune cells, and ER-β 
reactivity in the lymphocytic infiltrates has also been seen in breast tissue. (129-131) 
What is interesting is that in 2007, Pernis, et al showed that CD4+ T-lymphocytes 
expressed ER-α and B- lymphocytes expressed ER-β. (132) Considering that the 
lymphocytic infiltrates of SS comprise mainly T- lymphocytes, it is unusual that ER-α 
should be the least intense in our specimens. Furthermore, in 1995, Ono, et al, using 
a mouse model of SS was unable to demonstrate AR expression in the lymphocytic 
infiltrates within the lacrimal glands.(104)Future studies exploring the 
immunophenotyping of the inflammatory cell infiltrates of both AI-induced and 
traumatically induced inflammation would be valuable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
The data presented does not support the hypothesis as stated. Therefore we 
conclude that: 
No difference in the ratios of ER-α or ER-β to AR exists in MLSG biopsy 
specimens of patients with sicca syndrome regardless of focus score. 
However, the data has revealed other significant trends such as: 
1. In MLSG biopsies of SS patients, the likelihood of finding sex hormone 
receptor immunoreactivity is higher in the nucleus of the acinar cells 
regardless of which hormone is being evaluated. 
 
2. The likelihood of observing intense AR immunoreactivity in MLSG of Sjögren 
syndrome patients is 37.7 times greater than ER-α and 7.7 times greater than 
ER-β regardless of subcellular location. 
 
3. Mucous secretions within the glands of patients with sicca are 
immunoreactive with ER-α while they are not reactive in patients from the 
control group.  All other hormone receptors were not found in inspissated 
mucous secretions from any of the groups. 
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4. Lymphoplasmacytic foci within MLSG specimens were immunoreactive to 
ER-β, AR, and ER-α; and qualitatively more intense in the sicca patients than 
in the control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Future Direction 
 
 
 
1) Repeat the study with a larger sample size allowing for more elegant statistical 
analysis and reduction in the potential for type II statistical error. 
2) Based on the current results, reanalyzing the overall ER expression versus the 
overall AR without designation of  the glandular and subcellular compartments. 
This can be accomplished utilizing raw data scores as opposed to ratios of ER to 
AR. 
3) Intentional enrollment of age-, sex-matched control patients who have no clinical 
evidence of inflammation in the MLSGs. 
4) Prospective study where potential participants are identified and enrolled prior to 
MLSG biopsy so as to better control how specimens are handled prior to 
processing. This allows for comparison of reactivity of both fresh frozen as well 
as FFPE tissue. 
5) Compare results to clinical measurements of disease, clinical outcomes, 
response to therapies, etc. 
6) Attempt double-labeling of cells for better localization of hormone receptor 
expression within glands and within inflammatory cell infiltrates. 
a) Myoepithelial markers to highlight myoepithelial cells from acinar and luminal 
ductal cells 
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b) B- and T-cell markers to distinguish which cells are more  intensely staining 
with the hormone receptor antibodies 
7) Utilize laser capture micro-dissection to enable molecular studies on hormone 
receptor expression of acini vs. ducts vs. lymphoplasmacytic infiltrates. 
8) Improved methodology: 
(a) Intra-observer testing to validate reproducibility of the IHC scoring 
(b) Inter-observer testing to validate consistency in the FS of the sicca 
patients. 
(c) Utilize several analysis methods (manual and automated) for 
comparison of reproducibility and sensitivity. 
(d) Utilize digital cell counters to facilitate standard protocol for better 
quantification of numbers of cells reacting. 
(e) Section specimens at a thinner dimension to reduce overlap of cells 
within the glandular parenchyma. 
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